 |
|
Assessing the Assessment of Brain Serotonin Turnover
George M. Anderson, PhD
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
I would like to comment on several critical aspects of the January 2008 article of Barton and colleagues1 entitled "Elevated Brain Serotonin Turnover in Patients With Depression: Effect of Genotype and Therapy."
The authors indicate that measured internal jugular venoarterial (VA) differences in plasma levels of 5-hydroxyindoleacetic acid (5-HIAA, the major serotonin metabolite) are proportionally related to brain serotonin turnover. It is difficult to reconcile this view with the fact that observed individual VA differences were often quite close to or less than zero. Thus, the standard deviations observed for baseline VA gradients in both the major depressive disorder and control groups were similar to or greater than the means, and 6 of 11 patients with major depressive disorder appeared to have no VA gradient after selective serotonin reuptake inhibitor (SSRI) treatment. It seems inconceivable that a substantial fraction of subjects has little or no brain . . . [Full Text of this Article]
AUTHOR INFORMATION
RELATED ARTICLE
Elevated Brain Serotonin Turnover in Patients With Depression: Effect of Genotype and Therapy
David A. Barton, Murray D. Esler, Tye Dawood, Elisabeth A. Lambert, Deepak Haikerwal, Celia Brenchley, Florentia Socratous, Jacqueline Hastings, Ling Guo, Glen Wiesner, David M. Kaye, Richard Bayles, Markus P. Schlaich, and Gavin W. Lambert
Arch Gen Psychiatry. 2008;65(1):38-46.
ABSTRACT
| FULL TEXT
RELATED LETTER
Assessing the Assessment of Brain Serotonin Turnover—Reply
David A. Barton, Murray D. Esler, and Gavin W. Lambert
Arch Gen Psychiatry. 2008;65(10):1223-1224.
EXTRACT
| FULL TEXT
|
